According to the document disclosed by Hong Kong Stock Exchange on June 12, Jianxin Yang increased his shareholding on June 5 at an average price of HKD1.245 per share for 100,000 ordinary shares worth about HKD124,500. After the increase, Jianxin Yang's latest shareholding is 63.8743 million shares, with a warehouse ratio of 4.97%.$CSTONE PHARMA-B (02616.HK)$The value of the 100,000 ordinary shares is approximately HKD12.45 million. After the increase in shareholding, Jianxin Yang's latest shareholding is 63.8743 million shares, accounting for 4.97%.
Supplementary information: Box 28: These shares represent limited stock units and stock options, granted to or to be issued to Dr. Yang under the pre-IPO rsu Scheme, pre-IPO share option scheme, and post-IPO incentive plan, respectively. On January 16, 2019, a total of 3,237,580 limited stock units granted to Dr. Yang were all vested by February 16, 2023.What is equity disclosure?
According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the company's shares) must disclose their shareholding in the listed company. Directors and senior executives of the listed company must disclose their shareholding and equity certificate rights in the listed company and any related companies.
Why is equity disclosure important?
Equity disclosure enables investors to identify (1) individuals who control or have the ability to control the shareholding of the listed company and (2) individuals who may benefit from transactions involving entities related to the listed company.